Jiu'an Medical (002432.SZ)'s US subsidiary quadruple inspection and triple inspection products were notified before listing by the US FDA

Zhitong Financial App News, Jiu'an Healthcare (002432.SZ) announced that the following products of the company's US subsidiary iHealth Labs Inc. (“iHealth America”) have received a pre-marketing notice from the US Food and Drug Administration (FDA):

1. Household kit for quadruple testing of influenza A, influenza B, COVID-19 and RSV respiratory syncytial virus; professional kits for quadruple testing of influenza A, influenza B, COVID-19 and RSV respiratory syncytial virus received the US FDA 510 (K) pre-marketing notice (“quadruple test kit”).

2. Household kit for triple testing of influenza A, influenza B and COVID-19 viruses; professional kits for triple testing of influenza A, influenza B and COVID-19 viruses received the US FDA 510 (K) pre-marketing notice (“triple test kit”).

All of the above products can be sold normally in the US market after receiving pre-marketing notifications.